Vanda Pharmaceuticals Inc (VNDA)
R&D to Revenue
73.13%
Quarterly · Period ending:
VNDA R&D to Revenue
Latest reported73.13%period ending
Latest reported73.13%period ending
VNDA Quarterly R&D/Revenue (0.00% → 73.13%)
Latest values, visible window
High-resolution chart · PNG
VNDA r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 73.1323% | |
| 54.9809% | |
| 50.6956% | |
| 40.1063% | |
| 41.814% | |
| 71.3655% | |
| 37.3038% | |
| 35.206% | |
| 33.0091% | |
| 44.5704% | |
| 53.7629% | |
| 42.767% | |
| 36.1451% | |
| 30.7802% | |
| 28.6188% | |
| 38.0554% | |
| 33.3747% | |
| 34.8369% | |
| 28.42% | |
| 28.0377% | |
| 29.8208% | |
| 25.74% | |
| 21.9488% | |
| 20.392% | |
| 20.742% | |
| 26.7707% | |
| 21.4574% | |
| 19.0754% | |
| 18.5405% | |
| 27.8289% | |
| 24.3623% | |
| 23.181% | |
| 20.8363% | |
| 21.6003% | |
| 22.9334% | |
| 24.6226% | |
| 18.1853% | |
| 28.2427% | |
| 19.909% | |
| 18.9543% | |
| 18.5961% | |
| 22.6926% | |
| 27.464% | |
| 35.1891% | |
| 21.5575% | |
| 20.2167% | |
| 30.9174% | |
| 25.0372% | |
| 32.3513% | |
| 79.4378% | |
| 70.8414% | |
| 92.1575% | |
| 71.9077% | |
| 98.6614% | |
| 134.053% | |
| 122.5748% | |
| 149.0809% | |
| 149.6131% | |
| 126.1171% | |
| 102.5725% | |
| 80.7402% | |
| 56.8857% | |
| 49.2982% | |
| 56.1966% | |
| 28.994% | |
| 16.4292% | |
| 49.542% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 320.4406% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |